XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 175 filers reported holding XENON PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 1.28 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $6,598,053 | -9.3% | 171,378 | -15.7% | 0.55% | +8.9% |
| Q1 2023 | $7,275,105 | -33.1% | 203,272 | -26.3% | 0.51% | -46.7% |
| Q4 2022 | $10,871,009 | +16.0% | 275,704 | +6.2% | 0.95% | +17.2% |
| Q3 2022 | $9,371,993 | -33.9% | 259,612 | -44.3% | 0.81% | -19.4% |
| Q2 2022 | $14,173,013 | +13.1% | 465,911 | +13.6% | 1.01% | +4.8% |
| Q1 2022 | $12,534,342 | +91.5% | 410,021 | +95.7% | 0.96% | +130.1% |
| Q4 2021 | $6,545,374 | +706.2% | 209,519 | +192.7% | 0.42% | +106.9% |
| Q1 2020 | $811,842 | -71.3% | 71,591 | -66.8% | 0.20% | -59.5% |
| Q4 2019 | $2,826,634 | +45.5% | 215,609 | 0.0% | 0.50% | -17.2% |
| Q3 2019 | $1,942,637 | -12.2% | 215,609 | -3.9% | 0.60% | -2.6% |
| Q2 2019 | $2,211,992 | -3.0% | 224,340 | 0.0% | 0.62% | -6.9% |
| Q1 2019 | $2,279,294 | +76.1% | 224,340 | +9.4% | 0.66% | -5.1% |
| Q4 2018 | $1,294,206 | -53.3% | 205,104 | -2.2% | 0.70% | -42.3% |
| Q3 2018 | $2,768,555 | – | 209,739 | – | 1.22% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 266,961 | $9,119,388 | 10.70% |
| COMMODORE CAPITAL LP | 1,845,000 | $63,025,200 | 7.37% |
| TLS Advisors LLC | 32,956 | $1,126 | 4.56% |
| Altium Capital Management LP | 228,000 | $7,788,480 | 4.06% |
| Paradigm Biocapital Advisors LP | 1,491,835 | $50,961,084 | 3.46% |
| GREAT POINT PARTNERS LLC | 500,001 | $17,080,034 | 3.11% |
| DAFNA Capital Management LLC | 280,538 | $9,583,178 | 2.98% |
| Nan Fung Group Holdings Ltd | 106,680 | $3,644,189 | 2.95% |
| Affinity Asset Advisors, LLC | 300,438 | $10,262,962 | 2.89% |
| Avoro Capital Advisors LLC | 4,900,000 | $167,384,000 | 2.61% |